Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Up 44.9% in December

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 368 shares, an increase of 44.9% from the December 15th total of 254 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 3,296 shares, the short-interest ratio is presently 0.1 days. Based on an average trading volume of 3,296 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are sold short.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of institutional investors have recently added to or reduced their stakes in AAPG. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International during the 3rd quarter valued at about $383,000. XY Capital Ltd raised its stake in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the period. UBS Group AG boosted its holdings in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the last quarter. ABC Arbitrage SA purchased a new stake in shares of Ascentage Pharma Group International in the 3rd quarter valued at approximately $204,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Ascentage Pharma Group International during the 3rd quarter worth approximately $96,000.

Ascentage Pharma Group International Price Performance

AAPG opened at $27.05 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54. Ascentage Pharma Group International has a twelve month low of $16.50 and a twelve month high of $48.45. The firm’s 50-day moving average price is $29.68 and its 200 day moving average price is $35.78.

Analyst Ratings Changes

Several equities research analysts have commented on AAPG shares. BTIG Research started coverage on Ascentage Pharma Group International in a research report on Monday, November 10th. They issued a “buy” rating and a $50.00 price objective on the stock. Truist Financial set a $51.00 price target on shares of Ascentage Pharma Group International in a report on Monday, November 24th. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price on the stock. Finally, Oppenheimer initiated coverage on Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $48.40.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.